在进入风湿科诊疗前启动糖皮质激素与早期类风湿关节炎老年患者长期使用糖皮质激素相关:Medicare与风湿病信息学系统有效性(RISE)数据的联合分析
该研究链接RISE注册与Medicare数据,纳入1733例早期类风湿关节炎老年患者,评估糖皮质激素启动时机与进入风湿科诊疗及用药时长的关系。41%患者在进入风湿科诊疗前平均16±58天启动糖皮质激素,进入风湿科诊疗前启动与更长的糖皮质激素使用相关(HR 0.61,95%CI 0.51-0.74)。作者认为更早转诊风湿科可能减少美国早期类风湿关节炎患者的糖皮质激素暴露。
要点
- 41%的早期类风湿关节炎老年患者在进入风湿科诊疗前平均16±58天启动糖皮质激素。
- 进入风湿科诊疗前启动糖皮质激素与更长的使用时长相关(HR 0.61,95%CI 0.51-0.74)。
- 使用糖皮质激素≥3个月的患者平均每日泼尼松等效剂量<5 mg/d。
核心结论
- 糖皮质激素在早期类风湿关节炎中经常使用,且最常在患者进入风湿科诊疗前启动。
- 长期低剂量糖皮质激素使用常见,并与进入风湿科诊疗前启动相关。
- 作者认为更早转诊风湿科可能减少美国早期类风湿关节炎患者的糖皮质激素暴露。
研究设计与样本
- 联合分析链接风湿病信息学系统有效性(RISE)注册与美国Medicare(2016-2018年)数据。
- 纳入RISE中至少有2个类风湿关节炎ICD编码的患者,首个编码日期为索引日期,标志进入风湿科诊疗。
- 通过Medicare理赔数据捕获索引日期前3个月至后6个月间的糖皮质激素启动及索引日期后最长12个月的持续使用。
- 采用校正混杂因素的Cox比例风险模型评估索引日期前与后启动糖皮质激素的患者使用时长差异,并估算平均每日糖皮质激素剂量。
主要发现
- 共纳入1733例患者,67%为女性,平均年龄76±6岁。
- 41%的患者启动糖皮质激素,平均在进入风湿科诊疗前16±58天启动。
- 糖皮质激素平均使用时长157天(95%CI 143至170)。
- 校正混杂因素后,进入风湿科诊疗前启动糖皮质激素仍与更长的使用相关(风险比0.61;95%CI 0.51至0.74)。
- 使用糖皮质激素≥3个月的患者平均每日泼尼松等效剂量<5 mg/d。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess relationships between the timing of glucocorticoid (GC) initiation, entrance into rheumatology care, and the duration of GC use in older adults with early rheumatoid arthritis (eRA) in the U.S. METHODS: Data from the Rheumatology Informatics System for Effectiveness (RISE) registry and Medicare (2016-2018) were linked. Patients with ≥2 RA ICD codes in RISE were included; the first being the index date which signaled entrance into rheumatology care. GC initiation (between 3 months before to 6 months after the index date) and continuous GC use up to 12 months after the index date were captured using Medicare claims. Cox proportional hazards models with adjustment for confounders assessed differences in the duration of GC use for patients initiating GCs before versus after the index date. Average daily GC doses were estimated. RESULTS: 1,733 patients (67 % female; mean age 76 ± 6 years) were included. 41 % initiated GCs, on average 16 ± 58 days before entering rheumatologic care. The mean duration of GC use was 157 days (95 %-CI 143 to 170). GC initiation before rheumatologic care was associated with longer GC use, even after adjustment for confounders (hazard ratio 0.61; 95 %-CI [0.51 to 0.74]). For patients using GCs for ≥3 months, average daily GC doses were <5 mg/d prednisone equivalent. CONCLUSION: GCs are regularly used in eRA and most often initiated before patients enter rheumatology care. Long-term, low-dose GC use is common and associated with initiation before rheumatology care. Earlier referral to rheumatology might reduce GC exposure among U.S. patients with eRA.
引用
- Palmowski A, Roberts ET, Li J, et al. Initiation of glucocorticoids before entering rheumatology care associates with long-term glucocorticoid use in older adults with early rheumatoid arthritis: A joint analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) data. Semin Arthritis Rheum. 2024. PMID: 39182392. doi:10.1016/j.semarthrit.2024.152535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。